Literature DB >> 17313560

Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties.

Sheley Gambero1, Andreia A Canalli, Fabiola Traina, Dulcinéia M Albuquerque, Sara T O Saad, Fernando F Costa, Nicola Conran.   

Abstract

Propagation of the vaso-occlusive process in sickle cell anaemia (SCA) is a complex process involving the adhesion of steady-state SCA patients red cells and reticulocytes to the vascular endothelium. The effect of hydroxyurea therapy (HUT) on the adhesive properties of sickle cells and the expression of adhesion molecule genes by erythroid cells of SCA individuals is not yet fully understood. The expressions of the CD36 gene and the VLA-4-integrin subunit genes, CD49d (alpha-subunit) and CD29 (beta-subunit), were compared in the reticulocytes of steady-state SCA patients and patients on HUT using real-time PCR. Basal adhesion of red cells from these subjects was also compared using static adhesion assays, as was surface protein expression, using flow cytometry. Basal sickle red cell adhesion to fibronectin was significantly greater than that of normal cells (P < 0.01); in contrast, HUT was associated with significantly lower levels (P < 0.01) of red cell adhesion that were similar to those of control cells; this decrease could not be justified solely by altered reticulocyte numbers in this population. Accordingly, flow cytometry demonstrated that reticulocytes from patients on HUT had significantly lower CD36 and CD49d surface expressions (P < 0.01) and, importantly, significantly lower expressions of the CD36, CD49d and CD29 genes (P < 0.05) than reticulocytes of SCA patients not on HUT. Taken together, data support the hypothesis that HUT reduces the adhesive properties of sickle cells and that this decrease appears to be mediated, at least in part, by a decrease in the gene and, consequently, surface protein expression of adhesion molecules such as VLA-4 and CD36.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17313560     DOI: 10.1111/j.1600-0609.2006.00788.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  17 in total

Review 1.  Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Authors:  Ram Kalpatthi; Enrico M Novelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Biomechanics and biorheology of red blood cells in sickle cell anemia.

Authors:  Xuejin Li; Ming Dao; George Lykotrafitis; George Em Karniadakis
Journal:  J Biomech       Date:  2016-11-12       Impact factor: 2.712

Review 3.  The proteome of sickle cell disease: insights from exploratory proteomic profiling.

Authors:  Susan Yuditskaya; Anthony F Suffredini; Gregory J Kato
Journal:  Expert Rev Proteomics       Date:  2010-12       Impact factor: 3.940

4.  Effects of hydroxyurea on monoclonal antibody production induced by anti-mIgG and LPS stimulation on murine B cell hybridomas.

Authors:  Alicia Martín-López; Asterio Sánchez-Mirón; Francisco García-Camacho; Antonio Contreras-Gómez; Emilio Molina-Grima
Journal:  Cytotechnology       Date:  2010-05-21       Impact factor: 2.058

5.  Intercellular adhesion molecule-4 and CD36 are implicated in the abnormal adhesiveness of sickle cell SAD mouse erythrocytes to endothelium.

Authors:  Marie-Marcelle Trinh-Trang-Tan; Camilo Vilela-Lamego; Julien Picot; Marie-Paule Wautier; Jean-Pierre Cartron
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

6.  Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity.

Authors:  Farzin Pourfarzad; Marieke von Lindern; Azita Azarkeivan; Jun Hou; Sima Kheradmand Kia; Fatemehsadat Esteghamat; Wilfred van Ijcken; Sjaak Philipsen; Hossein Najmabadi; Frank Grosveld
Journal:  Haematologica       Date:  2012-10-25       Impact factor: 9.941

7.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

Review 8.  A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.

Authors:  Nirmani Yasara; Anuja Premawardhena; Sachith Mettananda
Journal:  Orphanet J Rare Dis       Date:  2021-03-01       Impact factor: 4.123

9.  Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.

Authors:  Yunus Alapan; Ceonne Kim; Anima Adhikari; Kayla E Gray; Evren Gurkan-Cavusoglu; Jane A Little; Umut A Gurkan
Journal:  Transl Res       Date:  2016-03-19       Impact factor: 7.012

Review 10.  Research in Sickle Cell Disease: From Bedside to Bench to Bedside.

Authors:  Gabriel Salinas Cisneros; Swee Lay Thein
Journal:  Hemasphere       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.